Archives

Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders

About this Course

Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

Target Audience

Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

This activity is NOT accredited for technicians.

Pharmacist Learning Objectives

At the end of this application-based continuing education activity, the learner will be able to:

Describe first- and second-line treatment options for the following disease states:

·        Schizophrenia

·        Bipolar disorder

·        Alcohol use disorder

·        Opioid use disorder

 
Identify where long-acting injectable medications fit into treatment guidelines for each disorder

 
Apply clinical treatment guidelines to select optimal pharmacologic treatment for a patient diagnosed with these disorders

Release Date

Released:  11/15/2023
Expires:  11/15/2026

Course Fee

$17

ACPE UAN

0009-0000-23-051-H01-P

Accreditation Hours

1.0 hours of CE

Session Code

23LA51-VXT88

Bundle Options

If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

You must register for ALL 4 activities to receive the bundled pricing of $299.00

Accreditation Statement

ACPE logo

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-051-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

Grant Funding

There is no grant funding for this activity.

Requirements for Successful Completion

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Faculty

Kristin Waters, PharmD, BCPS, BCPP,
Assistant Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

Disclaimer

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Program Content

Program Handouts

Post Test Evaluation

View Questions for Mental Illness and Substance Use Disorders: Background

Additional Courses Available for Long Acting Injectable Training

 

Mental Illness and Substance Use Disorders: Background - 1 hour

Long-Acting Injectable Medication Products– 1 hour

 

Mental Illness and Substance Use Disorders: Background

About this Course

 

 

Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

Target Audience

Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

This activity is NOT accredited for technicians.

Pharmacist Learning Objectives

At the end of this application-based continuing education activity, the learner will be able to:

Describe the prevalence, pathophysiology, clinical features, and diagnostic criteria of:

·        Schizophrenia

·        Bipolar disorder

·        Substance use disorders

 
Differentiate between signs and symptoms of these disorders

Release Date

Released:  11/15/2023
Expires:  11/15/2026

Course Fee

$17

ACPE UAN

0009-0000-23-050-H01-P

Accreditation Hours

1.0 hours of CE

Session Code

23LA50-TXJ44

Bundle Options

If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

You must register for ALL 4 activities to receive the bundled pricing of $299.00

Accreditation Statement

ACPE logo

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-050-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

Grant Funding

There is no grant funding for this activity.

Requirements for Successful Completion

To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

Faculty

Kristin Waters, PharmD, BCPS, BCPP,
Assistant Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

Disclaimer

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Program Content

Program Handouts

Post Test Evaluation

View Questions for Mental Illness and Substance Use Disorders: Background

Hour 1: Mental Illness and Substance Use Disorders: Background

1. A 38-year-old patient with an unknown psychiatric history is dropped off at the emergency department by police after being found wandering the streets and knocking on doors at random. The patient admits that they believe they are being monitored by the FBI and that “the mafia” wants to recruit them as a spy. The patient is observed having a conversation with themselves while alone in the examination room.

Which of the following positive symptoms is the patient likely experiencing?
A. Psychosis and auditory hallucinations
B. Auditory hallucinations and delusions
C. Delusions and anhedonia
D. Paranoia and agitation

2. Which of the following is the correct term for fixed, false beliefs that patients with schizophrenia may experience?
A. Delusions
B. Hallucinations
C. Disorganized speech
D. Catatonia

3. A patient with schizophrenia has experienced both positive and negative symptoms for several years. They are now presenting with signs of mania, including pressured speech and grandiosity. Which of the following is true?
A. The patient’s diagnosis will likely change to schizoaffective disorder, bipolar type
B. The patient’s diagnosis will likely change to schizoaffective disorder, depressive type
C. The patient will now be diagnosed with schizophrenia and bipolar disorder
D. The patient will now be diagnosed with schizophrenia and major depressive disorder

4. Which of the following is true about bipolar disorder?
A. The most common time that patients are diagnosed is during childhood
B. Most patients are initially diagnosed with schizophrenia
C. It has a higher mortality rate than major depressive disorder
D. Type II bipolar disorder is associated with more severe episodes of mania than type I

5. Most patients with bipolar disorder spend the majority of their time in which mood phase?
A. Mania
B. Depression
C. Hypomania
D. Euthymia

6. A patient with bipolar disorder presents to their outpatient provider and reports that they believe they are on the verge of a “breakthrough” and will soon become a world-famous author once their manuscript is published. They have recently stopped going to work and have been writing “all day and all night” for the past week. They also report spending thousands of dollars on a new computer so that they have “the best equipment” with which to write their manuscript.
Which of the following symptoms of mania is the patient displaying?
A. Grandiosity, decreased need for sleep, increased goal directed activity
B. Flight of ideas, distractibility, grandiosity
C. Disorganized thoughts, decreased need for sleep, flight of ideas
D. Confusion, excessive spending, distractibility

7. Patient NP was diagnosed with bipolar disorder, type II approximately 5 years ago. They have rarely missed work due to hypomanic symptoms, and are generally able to perform all day-to-day activities without impairment. Following a breakup, NP begins to display signs of grandiosity, flight of ideas, decreased sleep, and increased spending. They also begin to hear the voice of their ex-partner telling them that they are worthless.

Which of the following is most appropriate?
A. NP’s diagnosis should be changed to bipolar disorder type I
B. NP’s diagnosis should remain the same
C. NP’s diagnosis should be changed to schizoaffective disorder
D. NP’s diagnosis should be changed to bipolar disorder, mixed type

8. Which of the following is a risk factor for the development of a substance use disorder?
A. Female gender
B. Age > 65 years
C. Co-occurring psychiatric disorder
D. Parenthood

9. Which type of opioid receptor contributes to the stimulation of the dopamine-related reward system?
A. Mu-opioid receptor
B. Kappa-opioid receptor
C. Delta-opioid receptor
D. Beta-opioid receptors

Additional Courses Available for Long Acting Injectable Training

 

Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders– 1.0 hour

Long-Acting Injectable Medication Products– 1 hour

 

Patient Safety: Pharmacy Metrics-Recorded Webinar

About this Course

This course is a recorded (home study version) of the Pharmacy Metrics Webinar

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacy technician will be able to:

  • Describe the importance of pharmacy metrics for efficient operation.
  • Define pharmacy metrics in various settings.
  • Describe how team members can effectively contribute to the workplace

Release and Expiration Dates

Released:  September 15, 2023
Expires:  September 15, 2026

Course Fee

$4  Pharmacy Technician

ACPE UAN

0009-0000-23-026-H05-T

Session Code

20YC63-BCX86

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-026-H05-T, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Sara Miller, PharmD
CVS Pharmacist
Foxboro, MA

Kyra Durfee, PharmD Candidate 2022
UConn School of Pharmacy
Storrs, CT

Gabriella Scala, PharmD Candidate 2022
UConn School of Pharmacy
Storrs, CT 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Sara Miller, Kyra Durfee and Gabriela Scala have no relationships with ineligible companies and therefore nothing to disclose.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

1. Which of the following is NOT a use for metrics in pharmacies?
A. Quantify workflow
B. Exhaust staff
C. Establish comparators

2. Patient-centered metrics are based on which of the following?
A. Profits
B. Public health initiatives
C. Patient complaints

3. _____ is a metric used to assess productivity.
A. Time-to-fill
B. Rate of medication errors
C. Out-of-stock prescriptions

4. Which of the following is a good way to reach vaccination metrics?
A. Letting the patient contact the pharmacy about vaccinations
B. Reminding patients of vaccinations at the register
C. Relying on advertising to encourage patients

5. What does SMART goals, a great way to develop an approach to improve metrics, stand for?
A. Specific, Measurable, Achievable, Relevant, Time-Bound
B. Specific, Measurable, Achievable, Resourceful, Time-Bound
C. Specific, Measurable, Accurate, Reasonable, Time-Bound

6. What is the most important skill in the workplace when tackling metrics?
A. Speed
B. Communication
C. Knowledge

7. Many metrics focus on efficiency. What other consideration is crucial?
A. Type of pharmacy
B. Patient safety
C. Workload or volume

8. Select the statement that is TRUE:
A. Metrics usually refer to a general aspect of pharmacy tasks, so they are the same in community and clinical settings.
B. While metrics often refer to a general aspect of pharmacy tasks, they can vary greatly between community and clinical settings.
C. While metrics often refer to a general aspect of pharmacy tasks, pharmacies should stay away from standard metrics and develop new approaches.

9. Super Tech is worried about her pharmacy’s time-to-fill metric. Wonder Pharmacist is focused on inventory metrics. Three months go by and they haven’t made good progress on either. Why?
A. They are working alone on each metric, but need to be working together.
B. It’s not possible to work on two metrics at the same time.
C. Improving time-to-fill metrics will adversely influence inventory metrics.

10. Which of the following activity falls heavily on pharmacy technicians and contributes heavily to pharmacy metrics in the community setting?
A. Vaccinations
B. Insurance and billing
C. In-person patient interaction

Handouts

Download

VIDEO

Law: Psychedelic Drugs: Can They Make the “Trip” to the Pharmacy Shelf?-RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation is a Law CE revolving around psychodelic drugs used to treat Mental Health Disorders.

Learning Objectives

1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in
psychiatry, with an emphasis on psilocybin.
2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal
status.
3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

Session Offered

Released:  April 27, 2023
Expires:  April 27, 2026

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-23-011-H03-P

Session Code

23RW11-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-017-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Gerald Gianutsos, PhD, JD,
Professor Emeritus
University of Connecticut School of Pharmacy
Storrs, CT 

Faculty Disclosure

Dr. Gianutsos has no financial relationships with any ineligible company associated with this presentation.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Download

Post Test Pharmacist

Schwarting Webinar 2023 Post-Test

 

    1. Review the development of the knowledge of the effects of psychedelic drugs and their potential use in psychiatry, with an emphasis on psilocybin.
    2. Characterize the traditional legal classification of psychedelic drugs and modern reconsideration of their legal status.
    3. Describe efforts at the state level to expand the medical use of psychedelic drugs.

 

The tryptamine class of psychedelic drugs (e.g., LSD, psilocybin) produce their psychedelic/therapeutic effects by acting as agonists of a neurotransmitter in the CNS. What is the relevant neurotransmitter system?

 

  1. Serotonin
  2. Dopamine
  3. Glutamate

 

 

The FDA granted “breakthrough therapy” designation to psilocybin for treatment of a specific condition. What condition is it?

  1. Schizophrenia
  2. Treatment resistant depression
  3. Post traumatic stress disorder

 

 

 

Which feature distinguishes a C-I drug from other controlled substances?

  1. High potential for abuse, especially among hi-riskpopulations
  2. Lack of accepted safety for use under medical supervision
  3. No currently accepted medical use in treatment in the United States

 

 

Which state was the first to approve the use of psilocybin for medical use?

  1. California
  2. Oregon
  3. Maryland

 

 

A patient considering psilocybin treatment for a psychiatric disorder asks you for advice; he is specifically interested in disadvantages of this type of therapy. What do you tell him?

  1. Use of psychedelic therapy is time-and resource-intensive
  2. Requires multiple treatments with a slow onset of activity
  3. There is a high risk of autonomic side effects and addiction

 

 

In the state where medical use of psilocybin was first approved, which of the following statements describes its availability?

  1. Psilocybin can be purchased at retail outlets including pharmacies
  2. Psilocybin is available from any therapist throughout the state
  3. Psilocybin is only available in state licensed clinics

 

NAPLEX Calculation Review LIVE Event-2025

Are you studying for the NAPLEX EXAM?

NAPLEX Pharmacy Calculations Review 2025

Live Event-THIS WILL BE A LIVE IN-PERSON Event (no streaming)

Date:  Friday, May 16, 2025
Where:  Pharmacy Biology Building (PBB) Room 131
Time:  8:30 am – 4:30 pm
Cost:  $0

You MUST Register (even though there is no fee)

There is a fee for parking in the North Garage

Typical Schedule:

Friday

8:30-9:00     Check in and Presentation of Program and Review
9:00- 10:00  Diagnostic Test Administration
10:00-10:45  Review Answers t0 Diagnostic Test
10:45-11:00   Break
11:00-12:00   Students work on problem sets
12:00-1:00     Lunch
1:00-4:30       NAPLEX Calculations workshop

Lunch will be provided, please contact Alicia Scolaro at alicia.scolaro@uconn.edu with any dietary restrictions

 

CT Law Review Handouts

Are you new to Connecticut?

Do you need to take the Connecticut Law Exam for licensure?

Study Guide/Handouts from the 2025 program are now available for $50.

To Order the 2025 Handouts-$50 

CT Law Review LIVE Event-2025

Are you new to Connecticut?

Do you need to take the Connecticut Law Exam for licensure?

MPJE CT Law Review 2025

THIS WILL BE both IN PERSON and LIVE STREAMED.

Thursday, May 15, 2025
Time:  8:00 am-5:00 pm
Location:  Pharmacy Biology Building Room 131
Cost:  $200
There is a fee for parking in the North Garage

REGISTER

Typical Schedule:

8:20-8:30 Check-In
8:30-5:00 Law Review with break for lunch

Lunch will be provided-Please contact Alicia Scolaro at alicia.scolaro@uconn.edu if you have any dietary restrictions.

Click to order 2024 Law Review Handouts

Study Guide/Handouts from the 2025 program will be available for $50.

Register and Order the 2025 Handouts-COMING JUNE 2025

Replacement Immunization Certificates

Replacement Immunization Certificates

Have you lost or misplaced your Immunization Certificate?  If you attended the University of Connecticut School of Pharmacy’s “Immunization Training for Pharmacists” or you completed your Immunization Training as a UConn School of Pharmacy student, and need a replacement certificate, you can order your replacement copy online. The cost is $15  for the certificate. Just add to your cart!

ACPE logoCONTINUING EDUCATION CREDIT:
The University of Connecticut, School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Disclaimer:
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Immunization Training for Pharmacists 2023-2026

Practice Based Immunization Training for Pharmacists 2023-2026

This is a practice-based continuing education activity for pharmacists who plan to implement a pharmacist-directed immunization program at their practice site or fulfill the requirements to become a pharmacist immunizer.  This comprehensive and interactive continuing pharmacy education certification program is designed to meet various state regulations* for pharmacist immunizers.

*This activity meets state requirements for immunization in Connecticut (with current CPR certification).  For out of state participants please check your state regulations.  This is NOT the APhA activity.

Visit this site frequently for updated information or contact heather.kleven@uconn.edu  to be informed of new classes as they are scheduled.

THIS NEW & IMPROVED VERSION of Immunization Training for Pharmacists has added materials to make it a 21.5 hour activity-Newly accredited in 2023!

 NEXT DATE

July 30, 2025
Storrs, CT
7:30 AM – 5:00 PM
Cost:  $299

To REGISTER go to Orange Registration Button above

Brochure for full details

Requirements for Successful Completion

1.  Complete the 13.5 hours of online home study materials by signing into HuskyCT with your guest ID and password provided to you upon registration. View the activities, successfully complete the post-test learning assessments within HuskyCT.  You must complete all 20 activities to attend the live session.

2.  Attend and successfully complete the live activities to be held on:

July 30, 2025
LIVE/VIRTUAL Format
Storrs, CT

3. Please note: you must complete and maintain CPR certification, at your own expense and coordination, in order to fulfill the CT state requirements for a pharmacist immunizer. This will NOT be offered as part of this training.

4.  If necessary to have a Virtual format we will schedule in-person technique training and assessment following the Virtual/Live Events.  We will contact you with dates/times at various locations.

A total of 21.5 hours (including 8.0 live credits ) of practice-based continuing education credit will be issued upon successful completion of all required activities.

E-mail heather.kleven@uconn.edu  with questions.

Annual Continuing Education Updates for Pharmacists

State Regulations in Connecticut require pharmacists who have completed a practice-based immunization training to obtain continuing education on immunizations annually to maintain their certification. These activities are designed to fulfill the requirement and update pharmacists on current information. The credits can also be applied to your required 15 credits of annual CE.

Meet your annual Immunization Certification CE Requirement!

See the Immunization Section on our YAFI CE page

Immunization Resources

These are some valuable articles and tools for use in your Immunization practice.

https://www.immunize.org/

https://www.cdc.gov/vaccines/schedules/index.html

Understanding Vaccines

CONTINUING EDUCATION CREDIT:
ACPE LogoThe University of Connecticut, School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 21.5 contact hours (2.15 CEUs) will be awarded to pharmacists who view the presentations, pass the quizzes with a grade of 70% or better, and complete all evaluations. (ACPE #0009-23-004-CP) Statements of credit will be electronically transmitted to CPE Monitor within 72 hours of completing the activity.

Disclaimer:
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

A Review of Introductory Statistical Concepts (Optional)

Learning Objectives:

  1. Define a framework for the application of evidence-based medicine to clinical practice List the criteria that contribute to the quality of a trial
  2. Distinguish between categorical and continuous variables and how this impacts outcome assessment in a trial
  3. Interpret descriptive statistics in a given trial
  4. Define, interpret, and calculate a relative risk, odds ratio, relative and absolute risk, and number need to treat
  5. Use a 95% confidence interval to determine clinical and statistical significance
  6. Define type I and type II error and their impact on trial results

Activity Faculty

Diana Sobieraj, PharmD
Assistant Professor, Senior Research Scientist and Program Manager
University of Connecticut School of Pharmacy/Hartford Hospital Evidence-based Practice Center, Hartford, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Sobieraj has no relationship with an ineligible company.

Activity Fees

The fee for this activity is $20

Grant Funding

There is no grant funding for this activity.

Requirements for Successful Completion

ACPE LogoThe University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Two contact hours (0.2 CEU’s) will be awarded to pharmacists who view the presentation, pass the post test with a 70% or higher, and complete the evaluation. Statement of credit for 0009-0000-21-036-H04-P will be sent to CPE Monitor and can be printed from your CPE Monitor Profile.

Initial release date:  July 15, 2021
Planned expiration date:  July 15, 2024

Disclaimer:
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.